<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">porozendo</journal-id><journal-title-group><journal-title xml:lang="ru">Остеопороз и остеопатии</journal-title><trans-title-group xml:lang="en"><trans-title>Osteoporosis and Bone Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-2680</issn><issn pub-type="epub">2311-0716</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/osteo13152</article-id><article-id custom-type="elpub" pub-id-type="custom">porozendo-13152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Вторичный гиперпаратиреоз при хронической болезни почек у пациентов с сахарным диабетом: роль дефицита витамина D</article-title><trans-title-group xml:lang="en"><trans-title>Secondary hyperparathyroidism in chronic kidney disease in patients with diabetes mellitus: the role of vitamin D deficiency</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8642-9435</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авдеева</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Avdeeva</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валерия Александровна Авдеева, к. м. н.</p><p>625023; ул. Одесская, д. 54; Тюмень</p></bio><bio xml:lang="en"><p>Valeria A. Avdeeva, MD, PhD</p><p>625023; 54 Odesskaya street; Tyumen</p></bio><email xlink:type="simple">dr.avdeeva@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сячина</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Syachina</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Софья Николаевна Сячина, терапевт</p><p>625023; ул. Одесская, д. 54; Тюмень</p></bio><bio xml:lang="en"><p>Sofia N. Syachina, MD</p><p>625023; 54 Odesskaya street; Tyumen</p></bio><email xlink:type="simple">sonya.ya_3005@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9253-8075</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суплотова</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Suplotova</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Людмила Александровна Суплотова, д. м. н., профессор</p><p>Тюмень</p></bio><bio xml:lang="en"><p>Liudmila A. Suplotova, MD, PhD, Professor</p><p>Tyumen</p></bio><email xlink:type="simple">suplotovala@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Тюменский государственный медицинский университет<country>Россия</country></aff><aff xml:lang="en">Tyumen State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>17</day><month>04</month><year>2024</year></pub-date><volume>27</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Авдеева В.А., Сячина С.Н., Суплотова Л.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Авдеева В.А., Сячина С.Н., Суплотова Л.А.</copyright-holder><copyright-holder xml:lang="en">Avdeeva V.A., Syachina S.N., Suplotova L.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.osteo-endojournals.ru/jour/article/view/13152">https://www.osteo-endojournals.ru/jour/article/view/13152</self-uri><abstract><sec><title>   ОБОСНОВАНИЕ</title><p>   ОБОСНОВАНИЕ. Дефицит витамина D при вторичном гиперпаратиреозе (ВГПТ) на фоне хронической болезни почек (ХБП) у пациентов с сахарным диабетом (СД) является одним из ключевых факторов ухудшения функционирования почечного звена.</p></sec><sec><title>   ЦЕЛЬ</title><p>   ЦЕЛЬ. Оценить показатели кальций-фосфорного обмена у лиц с ВГПТ на фоне ХБП, СД и без него для оптимизации подходов к лечению.</p></sec><sec><title>   МАТЕРИАЛЫ И МЕТОДЫ</title><p>   МАТЕРИАЛЫ И МЕТОДЫ. Проведен ретроспективный анализ 416 историй болезни с диагнозами ХБПС3-С5 и ВГПТ, из которых 112 имели в анамнезе СД, находившиеся на обследовании и лечении в нефрологическом отделении в период с 01. 01. 2018 по 31. 12. 2022 гг. Изучены демографические и антропометрические данные, оценены лабораторные (общий и ионизированный кальций, общий белок, альбумин, фосфор, креатинин, паратиреоидный гормон, 25(OH)D,щелочная фосфатаза) и инструментальные (ЭХО-КГ, УЗИ органов брюшной полости и забрюшинного пространства) методы исследования.</p></sec><sec><title>   РЕЗУЛЬТАТЫ</title><p>   РЕЗУЛЬТАТЫ. СД является ведущей причиной ХБП среди всех нозологических форм. Уровень 25(OH)D у пациентов без СД варьировал от 9,04 до 152 нмоль/л, с СД — от 8,3 до 77 нмоль/л. Средний уровень 25(OH)D у пациентов без СД (41,7 ± 26,1 нмоль/л) достоверно выше, чем у пациентов с СД1 (20,3 ± 14,9 нмоль/л) и СД2 (27,6 ± 19,2 нмоль/л) (р = 0,005 и р = 0,003 соответственно). Дефицит и недостаточность 25(OH)D чаще регистрировались у пациентов с СД в сравнении с пациентами без СД (89 и 10 % против 69 и 19 % соответственно), при этом оптимальный уровень чаще встречался у пациентов без СД (12 и 1 % соответственно).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>   BACKGROUND</title><p>   BACKGROUND: Vitamin D deficiency in secondary hyperparathyroidism (SHPT) against the background of chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is one of the key factors in the deterioration of renal function.</p></sec><sec><title>   AIM</title><p>   AIM. To assess the indicators of calcium-phosphorus metabolism in individuals with SHPT against the background of CKD, diabetes and without it to optimize treatment approaches.</p></sec><sec><title>   MATERIALS AND METHODS</title><p>   MATERIALS AND METHODS. A retrospective analysis of 416 medical records with diagnoses CKD3-C5 and SHPT was carried out, of which 112 had a history of diabetes, which were examined and treated in the nephrology department of the in the period from 01. 01. 2018 to 31. 12. 2022. Demographic and anthropometric data were studied, laboratory (total and ionized calcium, total protein, albumin, phosphorus, creatinine, parathyroid hormone, 25(OH)D, alkaline phosphatase) and instrumental (ECHO-CG, ultrasound of the abdominal organs and retroperitoneal space) research methods.</p></sec><sec><title>   RESULTS</title><p>   RESULTS. Diabetes is the leading cause of CKD among all nosological forms. The level of 25(OH)D in patients without diabetes varied from 9.04 to 152 nmol/l, with diabetes from 8.3 to 77 nmol/l. The average level of 25(OH)D in patients without diabetes (41.7 ± 26.1 nmol/l) was significantly higher than in patients with type 1 diabetes (20.3 ± 14.9 nmol/l) and type 2 diabetes (27.6 ± 19.2 nmol/l) (p = 0.005 and p = 0.003, respectively). 25(OH)D deficiency and insufficiency were more often recorded in patients with diabetes compared with patients without carbohydrate disorders (89 % and 10 % versus 69 % and 19 % respectively), while the optimal level was more common in patients without diabetes (12 % and 1 %, respectively).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>25(OH)D</kwd><kwd>дефицит витамина D</kwd><kwd>вторичный гиперпаратиреоз</kwd><kwd>хроническая болезнь почек</kwd><kwd>сахарный диабет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>25(OH)D</kwd><kwd>vitamin D deficiency</kwd><kwd>secondary hyperparathyroidism</kwd><kwd>chronic kidney disease</kwd><kwd>diabetes mellitus</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена по инициативе авторов без привлечения финансирования</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The work was carried out on the initiative of the authors without attracting funding</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">https://kdigo.org/wp-content/uploads/2019/07/KDIGO_2018-Annual-Report.pdf. Электронный ресурс (дата обращения 03. 10. 2023)</mixed-citation><mixed-citation xml:lang="en">https://kdigo.org/wp-content/uploads/2019/07/KDIGO_2018-Annual-Report.pdf. Electronic resource (accessed 03. 10. 2023)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Румянцева Е.И. Хроническая болезнь почек как глобальная проблема для общественного здоровья: динамика заболеваемости и смертности // Проблемы стандартизации в здравоохранении. — 2021. — Т. 1. — № 2. — С. 41-49. doi: 10.26347/1607-2502202101-02041-049</mixed-citation><mixed-citation xml:lang="en">Rumyantseva E.I. Chronic kidney disease as a global public health problem: dynamics of morbidity and mortality. Problemy standartizacii v zdravoohranenii = Health care Standardization Problems. 2021(1-2):41-49. (in Russ.). doi: 10.26347/1607-2502202101-02041-049</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Викулова О.К., и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета на 01. 01. 2021 // Сахарный диабет. — 2021. — Т. 24. — № 3. — С. 204-221. doi: 10.14341/DM12759</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01. 01. 2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.). doi: 10.14341/DM12759</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhuri А, Ghanim H, Arora P. Improving residual risk of renal and cardiovascular outcomes in dkd: review of pathophysiology, mechanisms and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365-376. doi: 10.1111/dom.14601</mixed-citation><mixed-citation xml:lang="en">Chaudhuri А, Ghanim H, Arora P. Improving residual risk of renal and cardiovascular outcomes in dkd: review of pathophysiology, mechanisms and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365-376. doi: 10.1111/dom.14601</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">George C, Echouffo-Tcheugui JB, Jaar BG, et al. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low-and-middle income countries-a review of the current literature. BMC Med. 2022;20(1):247. doi: 10.1186/s12916-022-02438-6</mixed-citation><mixed-citation xml:lang="en">George C, Echouffo-Tcheugui JB, Jaar BG, et al. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low-and-middle income countries-a review of the current literature. BMC Med. 2022;20(1):247. doi: 10.1186/s12916-022-02438-6</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1. doi: 10.1016/j.kisu.2017.04.001</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1. doi: 10.1016/j.kisu.2017.04.001</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Егшатян Л.В., Мокрышева Н.Г. Вторичный гиперпаратиреоз при хронической болезни почек 3–4 стадии у пациента с сахарным диабетом 2 типа // Сахарный диабет. — 2018. — Т. 21. — № 2. — С. 128-134. doi: 10.14341/DM9458</mixed-citation><mixed-citation xml:lang="en">Egshatyan LV, Mokrisheva NG. Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease. Diabetes mellitus. 2018;21(2):128-134. (In Russ.). doi: 10.14341/DM9458</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">https://kdigo.org/wp-content/uploads/2022/12/Russian-Translation-KDIGO-2021-Glomerular-Diseases-Guideline.pdf. Электронный ресурс (дата обращения 03.10.2023)</mixed-citation><mixed-citation xml:lang="en">https://kdigo.org/wp-content/uploads/2022/12/Russian-Translation-KDIGO-2021-Glomerular-Diseases-Guideline.pdf.] Electronic resource (accessed 03. 10. 2023)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">https://euat.ru/education/calculator-egfr. Электронный ресурс (дата обращения 03. 10. 2023)</mixed-citation><mixed-citation xml:lang="en">https://euat.ru/education/calculator-egfr. Electronic resource (accessed 03. 10. 2023)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Бобкова И.Н., Ватазин А.В., Ветчинникова О.Н. и др. // Клинические рекомендации ассоциации нефрологов. Хроническая болезнь почек (ХБП). 2023 г.: 233С.</mixed-citation><mixed-citation xml:lang="en">Bobkova IN, Vatazin AV, Vetchinnikova ON, i dr. // Klinicheskie rekomendacii associacii nefrologov. Hronicheskaya bolezn' pochek (HBP). 2023 g.: 233S. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Белая Ж.Е. и другие // Клинические рекомендации Российской ассоциации эндокринологов по дефициту витамина D. — 2021 г.: 61 c.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Mel'nichenko GA, Belaya ZhE, i dr. Klinicheskie rekomendacii Rossijskoj associacii endokrinologov po deficitu vitamina D. 2021: 61 S. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet. 2018;392:2052–2090. doi: 10.1016/S0140-6736(18)31694-5</mixed-citation><mixed-citation xml:lang="en">Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet. 2018;392:2052–2090. doi: 10.1016/S0140-6736(18)31694-5</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation. IDF Diabetes Atlas, 10&lt;sup&gt;th&lt;/sup&gt; edn. Brussels, Belgium:International Diabetes Federation, 2021.</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation. IDF Diabetes Atlas, 10&lt;sup&gt;th&lt;/sup&gt; edn. Brussels, Belgium:International Diabetes Federation, 2021.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tervaert Thijs W Cohen, Mooyaart Antien L, Amann Kerstin, et al. On behalf of the Renal Pathology Society. Pathologic Classification of Diabetic Nephropathy. Journal of the American Society of Nephrology. 2010;21(4):556-563. doi: 10.1681/ASN.2010010010</mixed-citation><mixed-citation xml:lang="en">Tervaert Thijs W Cohen, Mooyaart Antien L, Amann Kerstin, et al. On behalf of the Renal Pathology Society. Pathologic Classification of Diabetic Nephropathy. Journal of the American Society of Nephrology. 2010;21(4):556-563. doi: 10.1681/ASN.2010010010</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Q, Sun J, Xu T, Bian G, Yang F. Associations of serum amyloid A and 25‐hydroxyvitamin D with diabetic nephropathy: A cross‐sectional study. J Clin Lab Anal. 2022;36(3). doi: 10.1002/jcla.24283</mixed-citation><mixed-citation xml:lang="en">Liu Q, Sun J, Xu T, Bian G, Yang F. Associations of serum amyloid A and 25‐hydroxyvitamin D with diabetic nephropathy: A cross‐sectional study. J Clin Lab Anal. 2022;36(3). doi: 10.1002/jcla.24283</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou T, Shen L, Li Z, et al. Severe 25-Hydroxyvitamin D Deficiency May Predict Poor Renal Outcomes in Patients With Biopsy-Proven Diabetic Nephropathy. Front Endocrinol (Lausanne). 2022;13. doi: 10.3389/fendo.2022.871571</mixed-citation><mixed-citation xml:lang="en">Zhou T, Shen L, Li Z, et al. Severe 25-Hydroxyvitamin D Deficiency May Predict Poor Renal Outcomes in Patients With Biopsy-Proven Diabetic Nephropathy. Front Endocrinol (Lausanne). 2022;13. doi: 10.3389/fendo.2022.871571</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ray S, Beatrice AM, Ghosh A, et al. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study. Diabetes Metab Syndr Clin Res Rev. 2017;11:S931-S937. doi: 10.1016/j.dsx.2017.07.019</mixed-citation><mixed-citation xml:lang="en">Ray S, Beatrice AM, Ghosh A, et al. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study. Diabetes Metab Syndr Clin Res Rev. 2017;11:S931-S937. doi: 10.1016/j.dsx.2017.07.019</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Duan S, Lu F, Wu B, et al. Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes. Front. Endocrinol. 2022;13:929598. doi: 10.3389/fendo.2022.929598</mixed-citation><mixed-citation xml:lang="en">Duan S, Lu F, Wu B, et al. Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes. Front. Endocrinol. 2022;13:929598. doi: 10.3389/fendo.2022.929598</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Xu F, Lu H, Lai T, et al. Chen Y. Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease. J. Diabetes Res. 2022;2022:9632355. doi: 10.1155/2022/9632355</mixed-citation><mixed-citation xml:lang="en">Xu F, Lu H, Lai T, et al. Chen Y. Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease. J. Diabetes Res. 2022;2022:9632355. doi: 10.1155/2022/9632355</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao X, Wang Y, Hou Y, et al. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J. Int. Med. Res. 2016;44:673–684. doi: 10.1177/0300060515593765.</mixed-citation><mixed-citation xml:lang="en">Xiao X, Wang Y, Hou Y, et al. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J. Int. Med. Res. 2016;44:673–684. doi: 10.1177/0300060515593765.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jamal Shahwan M, Hassan NAG, Shaheen RA. Assessment of kidney function and associated risk factors among type 2 diabetic patients. Diabetes Metab. Syndr. 2019;13:2661–2665. doi: 10.1016/j.dsx.2019.07.025</mixed-citation><mixed-citation xml:lang="en">Jamal Shahwan M, Hassan NAG, Shaheen RA. Assessment of kidney function and associated risk factors among type 2 diabetic patients. Diabetes Metab. Syndr. 2019;13:2661–2665. doi: 10.1016/j.dsx.2019.07.025</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Yang S, Zhou Q, et al. Effects of Vitamin D Supplementation on Renal Function, Inflammation and Glycemic Control in Patients with Diabetic Nephropathy : A Systematic Review and Meta-Analysis. Kidney Blood Press Res. 2019;44:72–87. doi: 10.1159/000498838</mixed-citation><mixed-citation xml:lang="en">Wang Y, Yang S, Zhou Q, et al. Effects of Vitamin D Supplementation on Renal Function, Inflammation and Glycemic Control in Patients with Diabetic Nephropathy : A Systematic Review and Meta-Analysis. Kidney Blood Press Res. 2019;44:72–87. doi: 10.1159/000498838</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Friedl C, Zitt E. Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis, 10 (2017), pp. 109-122. doi 10.2147/IJNRD.S97637</mixed-citation><mixed-citation xml:lang="en">Friedl C, Zitt E. Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis, 10 (2017), pp. 109-122. doi 10.2147/IJNRD.S97637</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Cardoso MP, Pereira LAL. Native vitamin D in pre-dialysis chronic kidney disease. Nefrologia (Engl Ed). 2019;39(1):18-28. English, Spanish. doi: 10.1016/j.nefro.2018.07.004</mixed-citation><mixed-citation xml:lang="en">Cardoso MP, Pereira LAL. Native vitamin D in pre-dialysis chronic kidney disease. Nefrologia (Engl Ed). 2019;39(1):18-28. English, Spanish. doi: 10.1016/j.nefro.2018.07.004</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
